Janssen Korea Introduces New Once-Daily Reminyl PR

Published: 2005-03-11 06:58:00

Updated: 2005-03-11 06:58:00

Janssen Korea announced early this week an availability of new, long-acting form of Reminyl PR (active ingredient: galantamine hydrobromide) for the treatment of mild to moderate Alzheimer's disease (AD) in the domestic market starting March.

According to the company, Reminyl PR capsules available in 8mg, 16mg and 24 mg dosage forms give an important, once-daily option for healthcare profess...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.